At WHO, Pharma Suggests Payment Plan For Influenza Virus UsePublished on 8 October 2012 @ 1:57 pm
By Rachel Marusak Hermann for Intellectual Property Watch
The World Health Organization advisory group on pandemic influenza preparedness met with pharmaceutical industry representatives, civil society members, and other stakeholders last week to move toward a recommendation on a partnership contribution formula to determine payment modalities for influenza virus sharing.
The cash-strapped UN health organisation is keen to get partners to pay for their use of the Pandemic Influenza Preparedness (PIP) benefit sharing system by the end of the year. So advancing the partnership contribution was a top priority for the PIP advisory group, which met from 3-5 October at the WHO.
Member States adopted the PIP Framework [pdf] over a year ago during the 64th World Health Assembly to ensure the fair access and sharing of influenza viruses, vaccines, and other benefits by all countries. So far, influenza viruses are being shared, but industry partners have not yet paid for the use of the system
Under Section 6.14 of the PIP Framework, influenza vaccine, diagnostic and pharmaceutical manufacturers, using the WHO Global Inﬂuenza Surveillance and Response System (GISRS), are expected to pay half of its operating cost -about US$ 28 million annually.
“It is true that viruses are being shared, so the benefits should be shared. It is a bit surprising that in an age when you can transfer money with the click of a button that making payments take more time than sharing viruses,” Professor Didier Houssin, PIP advisory group chair, told Intellectual Property Watch.
One payment plan, put forth by the pharmaceutical industry, has been suggested and its basic tenets were well received during the consultations.
An Offer on the Table
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) submitted a revenue-based proposal to the WHO Secretariat on 5 September. During the industry and civil society joint consultations, Michael Watson, vice president of vaccination policy and advocacy at Sanofi Pasteur, presented elements of the proposal on behalf of the association.
“We spent six months working on this with a third party, thinking very carefully how to achieve this. It is based on a combination of pandemic and seasonal revenues,” Watson said.
Representatives of the Biotechnology Industry Organization (BIO) and AdvaMedDx, a diagnostic manufacturers advocacy organisation, also present during the consultations, expressed their support for the IFPMA proposal, which bases the partnership contribution on influenza vaccine sales.
When asked for more details on the contribution breakdown, Watson explained, “Our proposal has three elements to it. It has an element of pandemic sales from the past pandemic, it has an element of seasonal sales, and pre-pandemic sales.”
Members of non-governmental organisations (NGOs) including Knowledge Ecology International (KEI) and the Third World Network (TWN) requested to review the proposal. At the time of this writing, the WHO Secretariat has not responded to additional requests to make the proposal public.
Also in an effort to define who should start contributing to the PIP benefit-sharing system, the advisory group likely will recommend the need to establish a comprehensive list of vaccine manufacturers with their development and/or production capabilities through a questionnaire which will be developed by the WHO Secretariat.
Although the IFPMA proposal is widely supported by industry, there may other ideas circulating in terms of how to approach contributions.
During the consultations with civil society, WHO Director General Margaret Chan, who was also present during industry consultations, said: “Industry is not homogenous and they may have different opinions, different positions. We are listening to industry from developing countries. DCVMN [Developing Countries Vaccine Manufacturers Network] was connected by teleconference and gave us their view and opinion, and we listened.”
The director general was also very receptive to hearing the ideas put forth by civil society groups, which also included the Berne Declaration and the Medicines Patent Pool (MPP). One key issue evoked was the importance of including the full scope of users benefiting from the WHO virus sharing system.
Sangeeta Shashikant, TWN coordinator and legal advisor, pointed to the broad definition of “influenza vaccine, diagnostic and pharmaceutical manufacturers” under Section 4.1 in the Framework, which includes “academic institutions, government owned or government subsidized entities, non-proﬁt organizations or commercial entities that develop and/or produce human inﬂuenza vaccines and other products derived from or using H5N1 or other inﬂuenza viruses of human pandemic potential.”
In order to capture some of the value that comes from the use of PIP biological material that is not necessarily measurable by vaccine sales, such as the acquisition and licensing of intellectual property rights, James Love, director of KEI, suggested an additional measure by which users would self-evaluate these assets.
“Companies would establish how they value their intellectual property rights in the narrow area of the field-of-use licence and the assessment would be based upon that self-evaluation. The understanding would be that the WHO could acquire the licence or they could assign it to someone else to acquire it for whatever the self-evaluation is, which would be a disincentive for undervaluing it,” Love explained.
KEI will submit further details on how self-evaluation of IPR would work in this context to the WHO Secretariat in the coming weeks.
Although there may not be unanimity amongst all stakeholders, the advisory group was pleased to see broad convergence around basing contributions on influenza vaccine revenues as a starting point.
“Of course it would be ideal to be perfect, to have a definition that covers all manufacturers, but since things have to go rapidly, it is important if we could define and start with a first group of manufacturers,” Chair Houssin told Intellectual Property Watch.
Beyond the partnership contribution, the advisory group also discussed how funds would be allocated once they are collected. The WHO Executive Board adopted the advisory group’s recommendation to allocate 70 per cent of contributions for preparedness and 30 per cent for response activities last May (IPW, WHO, 26 May 2012).
During these consultations, the chair emphasised during a presentation [PPT] that the PIP Framework principles should be taken into account, including “fairness, equity, public health risk and need of all Member States and the particular vulnerability of H5N1.”
Houssin added that the allocations should be “evidence based and consider indicators adapted to the Framework such as IHR [International Health Regulations] core capacity, income, health and epidemiology.”
During the consultations, the WHO Secretariat provided an update on the negotiations of Standard Material Transfer Agreements 2 (SMTA 2), the contracts that allow the sharing of viruses with entities outside the WHO GISRS.
There are currently five contracts being negotiated with companies, including GSK, Sanofi, Novartis, Baxter, Serum Institute of India. The Secretariat hopes that one will be concluded by the end of the year.
The advisory group will submit its suggestions to the Director General who will present her recommendations at the Executive Board meeting in January 2013. The advisory group is looking at reconvening next March, but a date has not yet been confirmed.
Rachel Marusak Hermann may be reached at email@example.com.